Have changing pneumococcal vaccination programmes impacted disease in Ontario?

被引：16

作者：

Lim, Gillian H. ^{[1
]}

Wormsbecker, Anne E. ^{[1
,2
]}

McGeer, Allison ^{[3
,4
,5
]}

Pillai, Dylan R. ^{[6
,7
,8
,9
]}

Gubbay, Jonathan B. ^{[4
,6
]}

Rudnick, Wallis ^{[3
,5
,10
]}

Low, Don E. ^{[3
,4
,5
,6
]}

Green, Karen ^{[5
,11
]}

Crowcroft, Natasha S. ^{[4
,10
,12
]}

Deeks, Shelley L. ^{[1
]}

机构：

[1] Publ Hlth Ontario, Toronto, ON, Canada

[2] Hosp Sick Children, Div Paediat Med, Toronto, ON M5G 1X8, Canada

[3] Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada

[4] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[5] Toronto Invas Bacterial Dis Network, Toronto, ON, Canada

[6] Publ Hlth Ontario Lab, Toronto, ON, Canada

[7] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada

[8] Univ Calgary, Dept Med, Calgary, AB, Canada

[9] Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB, Canada

[10] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada

[11] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada

[12] Publ Hlth Ontario, Communicable & Infect Dis, Toronto, ON, Canada

来源：

VACCINE | 2013年 / 31卷 / 24期

关键词：

Streptococcus pneumonia; Invasive pneumococcal disease; Epidemiology; Immunization programme impact; Pneumococcal vaccines; Canada; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; ANTIMICROBIAL SUSCEPTIBILITIES; CANADIAN CHILDREN; INFECTIONS; INFANTS; IMMUNIZATION; EPIDEMIOLOGY; 19A;

D O I：

10.1016/j.vaccine.2013.04.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Publicly funded infant 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in Ontario, Canada in 2005 and was replaced by 10- and 13-valent vaccines (PCV10, PCV13) in October 2009 and November 2010, respectively. Among adults >= 65 years, a 23-valent polysaccharide vaccine (PPV23) has been universally available since 1996. In January 2012, PCV13 was approved for adults >= 50 years. This study examines the impact of publicly funded vaccination programmes on invasive pneumococcal disease (IPD). Methods: Laboratory data from population-based surveillance for IPD conducted at the Toronto Invasive Bacterial Disease Network and from Public Health Ontario Laboratories between January 1, 2008 and December 31, 2010 were analyzed. Results: Between 2008 and 2010 there were 3259 cases of IPD; overall incidence was 7.4/9.3/8.3 per 100,000 in 2008/9/10, respectively. Incidence increased significantly among adults 65+ years during the period; this group had the highest incidence (21.5-25.6/100,000). The second highest incidence in 2008 and 2009 was in infants <1 year, whereas in 2010 it was in children 1-4 years. Among children <5 years, 68% and 19% of serotypes were covered by PCV13 and PCV10, respectively, between 2008 and 2010. In 2009, 6 cases with the 3 additional PCV10 serotypes were reported in infants compared with 2 in 2010. Among persons eligible for PCV7 (born >= 2004), there was a 77% decrease in the rate of IPD due to PCV7 serotypes between 2008 and 2010 and a 60% decrease in PCV7 serotypes among persons not vaccine-eligible (born<2004). There was a 15% difference in serotype coverage between PCV13 and the 23-valent polysaccharide vaccine in adults >= 50 years. Conclusions: During Ontario's PCV7 programme, serotype-specific decreases in IPD were observed, suggesting vaccine programme success, including herd immunity. Our results also suggest some early impact among infants from PCV10 introduction. A substantial burden of disease was also observed among older adults. Crown Copyright (C) 2013 Published by Elsevier Ltd. All rights reserved.

引用

页码：2680 / 2685

页数：6

共 32 条

[1]

[Anonymous], 2006, Can Commun Dis Rep, V32, P157

[2]

[Anonymous], 2006, Can Commun Dis Rep, V32, P117

[3]

[Anonymous], MMWR

[4]

[Anonymous], 2010, PDF REPORT